Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Denali Advisors LLC

Denali Advisors LLC boosted its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,000 shares of the medical equipment provider’s stock after purchasing an additional 300 shares during the period. Denali Advisors LLC’s holdings in Hologic were worth $371,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of Hologic in the 4th quarter worth $217,529,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after purchasing an additional 2,753,016 shares during the period. Swedbank AB purchased a new position in shares of Hologic in the 1st quarter worth about $120,827,000. The Manufacturers Life Insurance Company lifted its stake in shares of Hologic by 117.4% in the 4th quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock valued at $154,598,000 after purchasing an additional 1,168,564 shares in the last quarter. Finally, Black Creek Investment Management Inc. grew its holdings in shares of Hologic by 60.9% during the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after purchasing an additional 885,524 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insider Buying and Selling

In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the sale, the chief executive officer now directly owns 1,157,562 shares in the company, valued at $92,755,443.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Stephen P. Macmillan sold 3,672 shares of the stock in a transaction dated Wednesday, July 17th. The shares were sold at an average price of $80.13, for a total value of $294,237.36. Following the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Brandon Schnittker sold 476 shares of Hologic stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the completion of the sale, the insider now owns 3,735 shares in the company, valued at $310,415.85. The disclosure for this sale can be found here. Insiders sold a total of 18,280 shares of company stock worth $1,469,973 in the last three months. 1.75% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on HOLX shares. Stephens reiterated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Evercore ISI lifted their price objective on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research note on Tuesday, July 30th. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Tuesday. StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 30th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $87.60.

Hologic Trading Down 0.8 %

NASDAQ HOLX opened at $82.00 on Wednesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. Hologic, Inc. has a one year low of $64.02 and a one year high of $84.67. The company has a 50-day simple moving average of $80.36 and a 200-day simple moving average of $76.92. The firm has a market capitalization of $19.14 billion, a PE ratio of 41.84, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. Hologic’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.93 earnings per share. On average, equities analysts forecast that Hologic, Inc. will post 4.09 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.